Asthma Clinical Trials in New York, New York

8 studies are recruiting for asthma in New York, New York right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study Evaluating Disease Characteristics and Outcomes in Participants With Asthma in Routine Clinical Practice

   The main aim of the study to describe the characteristics of participants with asthma across the spectrum of disease severity, including sociodemographic and clinical characteristics, treatment and disease burden, biomarkers, and both disease-specific and generic health-related quality of life. The…

   Stage

   Not phased

   Ages

   6 and older

   Site

   Icahn School of Medicine at Mount Sinai - Center for Advanced Medicine - Site Number: 840119, New York, New York

   Locations

   62 in total

   Run by

   Sanofi

   See if you can join NCT07556159 on ClinicalTrials.gov

2. Registry of Asthma Characterization and Recruitment 3 (RACR3)

   This is a multi-center, non-interventional registry to create and maintain a database of participants to serve as a recruitment source for current and future DAIT NIAID-sponsored Childhood Asthma in Urban Settings (CAUSE) studies.

   Stage

   Not phased

   Ages

   Any age

   Site

   Icahn School of Medicine at Mount Sinai: Division of Clinical Immunology, Immunology Institute, New York, New York

   Locations

   7 in total

   Run by

   National Institute of Allergy and Infectious Diseases (NIAID)

   See if you can join NCT05272241 on ClinicalTrials.gov

3. A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma

   The purpose of this study is to assess the safety and efficacy of brenipatide at different dose levels compared with placebo in participants with moderate-to-severe asthma. Study participation will last approximately 65 weeks, including screening, treatment, and follow-up periods.

   Stage

   Phase 2

   Ages

   18 to 75

   Site

   Equity Medical, New York, New York

   Locations

   121 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07219173 on ClinicalTrials.gov

4. Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma

   The purpose of this study is to compare the effect of budesonide/albuterol metered-dose inhaler (BDA MDI) with albuterol sulfate metered-dose inhaler (AS MDI), both administered as needed, on the annualized rate of severe asthma exacerbations in adolescents with a documented clinical diagnosis of a…

   Stage

   Phase 3

   Ages

   12 to 17

   Site

   Research Site, New York, New York

   Locations

   150 in total

   Run by

   AstraZeneca

   See if you can join NCT06307665 on ClinicalTrials.gov

5. Asthma Symptom Perception Study

   Asthma affects 8% of the United States population ages >60 years and causes considerable harm: older adults are 4 times more likely to die from asthma and have twice the risk of hospitalization. The burden of asthma is notably greater among minoritized older adults. Research suggests that perceptio…

   Stage

   Not phased

   Ages

   60 and older

   Site

   Ichan School of Medicine at Mount Sinai, New York, New York

   Locations

   2 in total

   Run by

   Icahn School of Medicine at Mount Sinai

   See if you can join NCT06612294 on ClinicalTrials.gov

6. Depemokimab Asthma Imaging and Bronchoscopy Sub-Study

   Asthma is a chronic condition marked by narrowed and swollen airways due to inflammation leading to recurring symptoms that can vary and worsen unpredictably.\xa0The purpose of this study is to assess how depemokimab, a monoclonal antibody, affects the structure and function of the lungs in asthmat…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   GSK Investigational Site, New York, New York

   Locations

   50 in total

   Run by

   GlaxoSmithKline

   See if you can join NCT06979323 on ClinicalTrials.gov

7. Protocol CAUSE-03 / CHEETAH

   This is a one-year longitudinal, observational study of 250 urban children and adolescents with asthma and 60 without asthma, ages 6-17 years old. Participants with asthma will require daily controller therapy with inhaled corticosteroids ICS (at least Step 2 therapy). Those without asthma cannot h…

   Stage

   Not phased

   Ages

   6 to 17

   Site

   Icahn School of Medicine at Mount Sinai: Division of Clinical Immunology, Immunology Institute, New York, New York

   Locations

   8 in total

   Run by

   National Institute of Allergy and Infectious Diseases (NIAID)

   See if you can join NCT06136091 on ClinicalTrials.gov

8. Individualizing Treatment for Asthma in Primary Care (Full Study)

   While asthma therapy is becoming more individualized based on asthma phenotypes, more research is needed to tailor newer therapies to individuals. Inhaled corticosteroid (ICS) medications are the foundation of care for all individuals with persistent asthma. But ICS use is not without possible long…

   Stage

   Phase 4

   Ages

   13 to 75

   Site

   Mt. Sinai School of Medicine, New York, New York

   Locations

   13 in total

   Run by

   DARTNet Institute

   See if you can join NCT07052942 on ClinicalTrials.gov